(Q43868911)

27 November 2017

title

Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy (English)

1 reference

Helicobacter pylori infectious disease

27 November 2017

1 reference

1 reference

1 reference

1 reference

K Murakami

1

1 reference

27 November 2017

T Fujioka

2

1 reference

27 November 2017

T Okimoto

3

1 reference

27 November 2017

R Sato

4

1 reference

27 November 2017

M Kodama

5

1 reference

27 November 2017

M Nasu

6

1 reference

27 November 2017

language of work or name

1 reference

1 January 2002

1 reference

International Journal of Antimicrobial Agents

27 November 2017

published in

1 reference

27 November 2017

volume

19

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

67-70

1 reference

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

The report of the Digestive Health InitiativeSM International Update Conference on Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Clinical relevance of resistant strains of Helicobacter pylori: a review of current data

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Resistance of Helicobacter pylori to antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Eradication of Helicobacter pylori with clarithromycin and omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900456-3

7 January 2021

10.1016/S0924-8579(01)00456-3

Identifiers

DOI

1 reference

27 November 2017

1 reference